



**PHARMACY AND THERAPEUTICS COMMITTEE
 MEDICARE MEETING MINUTES
 PPO-POS, HMO-POS, HMO-SNP
 February 26, 2026**

*Attendance: Microsoft Teams Meeting
 Gary Bledsoe, Staff/Clinical Pharmacist; Dr. Edgar Chou, Jefferson Health; Jerry Crawford, Staff/Clinical Pharmacist; Dr. Neal Demp, Community Behavior Health; Danielle Dolores, Director Pharmacy Services; Dr. George E. Downs, Dean Emeritus and Professor, St. Joseph’s University; Leah Finken, Clinical Programs Pharmacist; Hailey Fry, Centennial Pharmacy; Paul Goebel, Assistant Director Pharmacy, Jefferson Enterprise; Dr. Merleen Harris-Williams, Medical Director; Yelena Hedrick, Staff/Clinical Pharmacist; Gia Ho, Pharmacy Resident; Jessica (Tran) Hoang-Le, Staff/Clinical Pharmacist; Samantha Jackson, Formulary Pharmacist; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Hannah McCaffrey, Manager Pharmacy Regulations & Implementations; Lisa Murray, Staff/Clinical Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Kateryna Puia, Clinical Programs Pharmacist; Sara Sadiq, Staff/Clinical Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovec, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Staff/Clinical Pharmacist; Brian Swift, Enterprise Vice President/Chief Pharmacy Officer, Jefferson Health; Fallan Vaisberg, Formulary Pharmacist; Jeanine Zubrzycki, Staff/Clinical Pharmacist*

Excused: Dr. Paul Aitken, Medical Director; Connie Chan, Staff/Clinical Pharmacist; Dr. Demian Elder, Medical Director; Sharon Ford, Staff/Clinical Pharmacist; Ruth John, Staff/Clinical Pharmacist; Brandi Mahler, Supervisor Pharmacy Technicians; Sanjiv Raj, Associate VP Customer Engagement; Julie Samuel, Clinical Programs Pharmacist; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health

Minutes taken by: Joana Iverson

I. Administrative Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING	DUE DATE
<i>Minutes Review/Approval</i>	<i>D. Dolores presented the minutes from the October 2025 meeting to the Committee for review.</i>	<i>The Committee approved the minutes from our last meeting as presented.</i>	<i>D. Dolores</i>	<i>Resolved</i>	
<i>2025 Year in Review</i>	<i>D. Dolores presented the 2025 Year in Review.</i> <ul style="list-style-type: none"> • <i>Prior Authorizations</i> 		<i>D. Dolores</i>	<i>Informational</i>	

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING	DUE DATE
	<ul style="list-style-type: none"> Top 10 Drugs and Drug Classes 				
2026 Medicare Membership	<i>D. Dolores presented 2026 membership.</i>		<i>D. Dolores</i>	<i>Informational</i>	

II. Drug Formulary Review/Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING	DUE DATE																								
2026 Prior Authorization Criteria Updates – Outlier Review	<i>The Committee reviewed the 2026 Prior Authorization Criteria updates – outlier review. The Committee approved as presented:</i>	<i>The Committee approved the 2026 Prior Authorization Criteria updates – outlier review. It will be sent to CMS for approval. (See attached for voting detail)</i>	<i>S. Jackson</i>	<i>Resolved</i>																									
	<table border="1"> <thead> <tr> <th>Criteria Name</th> <th>6T Premium (HMO-SNP)</th> <th>5T Core (PPO, HMO)</th> <th>5T Value (PPO, HMO)</th> </tr> </thead> <tbody> <tr> <td><i>Kerendia</i></td> <td><i>X</i></td> <td><i>X</i></td> <td><i>X</i></td> </tr> <tr> <td><i>Rinvoq</i></td> <td><i>X</i></td> <td><i>X</i></td> <td><i>X</i></td> </tr> <tr> <td><i>Tocilizumab</i></td> <td><i>X</i></td> <td><i>X</i></td> <td><i>X</i></td> </tr> </tbody> </table>					Criteria Name	6T Premium (HMO-SNP)	5T Core (PPO, HMO)	5T Value (PPO, HMO)	<i>Kerendia</i>	<i>X</i>	<i>X</i>	<i>X</i>	<i>Rinvoq</i>	<i>X</i>	<i>X</i>	<i>X</i>	<i>Tocilizumab</i>	<i>X</i>	<i>X</i>	<i>X</i>								
	Criteria Name					6T Premium (HMO-SNP)	5T Core (PPO, HMO)	5T Value (PPO, HMO)																					
	<i>Kerendia</i>					<i>X</i>	<i>X</i>	<i>X</i>																					
<i>Rinvoq</i>	<i>X</i>	<i>X</i>	<i>X</i>																										
<i>Tocilizumab</i>	<i>X</i>	<i>X</i>	<i>X</i>																										
2026 Prior Authorization Criteria Updates	<i>The Committee reviewed the 2026 Prior Authorization Criteria Updates. The Committee approved as presented:</i>	<i>The Committee reviewed the 2026 Prior Authorization Criteria Updates. It will be sent to CMS for approval. (See attached for voting detail)</i>	<i>S. Jackson</i>	<i>Resolved</i>																									
	<table border="1"> <thead> <tr> <th>Criteria Name</th> <th>6T Premium (HMO-SNP)</th> <th>5T Core (PPO, HMO)</th> <th>5T Value (PPO, HMO)</th> </tr> </thead> <tbody> <tr> <td><i>High-Risk Medications – Diazepam</i></td> <td><i>X</i></td> <td><i>X</i></td> <td><i>X</i></td> </tr> <tr> <td><i>High-Risk Medications – Lorazepam</i></td> <td><i>X</i></td> <td><i>X</i></td> <td><i>X</i></td> </tr> <tr> <td><i>High-Risk Medications – Temazepam</i></td> <td><i>X</i></td> <td><i>X</i></td> <td><i>X</i></td> </tr> <tr> <td><i>Tremfya</i></td> <td><i>X</i></td> <td><i>X</i></td> <td><i>X</i></td> </tr> <tr> <td><i>Ustekinumab</i></td> <td><i>X</i></td> <td><i>X</i></td> <td><i>X</i></td> </tr> </tbody> </table>					Criteria Name	6T Premium (HMO-SNP)	5T Core (PPO, HMO)	5T Value (PPO, HMO)	<i>High-Risk Medications – Diazepam</i>	<i>X</i>	<i>X</i>	<i>X</i>	<i>High-Risk Medications – Lorazepam</i>	<i>X</i>	<i>X</i>	<i>X</i>	<i>High-Risk Medications – Temazepam</i>	<i>X</i>	<i>X</i>	<i>X</i>	<i>Tremfya</i>	<i>X</i>	<i>X</i>	<i>X</i>	<i>Ustekinumab</i>	<i>X</i>	<i>X</i>	<i>X</i>
	Criteria Name					6T Premium (HMO-SNP)	5T Core (PPO, HMO)	5T Value (PPO, HMO)																					
	<i>High-Risk Medications – Diazepam</i>					<i>X</i>	<i>X</i>	<i>X</i>																					
	<i>High-Risk Medications – Lorazepam</i>					<i>X</i>	<i>X</i>	<i>X</i>																					
	<i>High-Risk Medications – Temazepam</i>					<i>X</i>	<i>X</i>	<i>X</i>																					
<i>Tremfya</i>	<i>X</i>	<i>X</i>	<i>X</i>																										
<i>Ustekinumab</i>	<i>X</i>	<i>X</i>	<i>X</i>																										
2026 Step Therapy Removals	<i>The Committee reviewed the 2026 Step Therapy Removals. The Committee approved as presented:</i> <ul style="list-style-type: none"> <i>Jardiance ST</i> 	<i>The Committee reviewed the 2026 Step Therapy Removals. It will be sent to CMS for approval. (See attached for voting detail)</i>	<i>S. Jackson</i>	<i>Resolved</i>																									

TOPIC	DISCUSSION				ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING	DUE DATE
2026 Formulary Additions	<i>The Committee reviewed the 2026 Formulary Additions. The Committee approved as presented:</i>				<i>The Committee reviewed the 2026 Formulary Additions. It will be sent to CMS for approval. (See attached for voting detail)</i>	<i>S. Jackson</i>	<i>Resolved</i>	
	Drug Name	6T Premium (HMO-SNP)	5T Core (PPO, HMO)	5T Value (PPO, HMO)				
	<i>Exxua Titration Pack</i>	<i>T5, PA, QL</i>	<i>T5, PA, QL</i>	<i>T5, PA, QL</i>				
	<i>Fanapt Titration Pack B tablet</i>	<i>T5, ST, QL</i>	<i>T5, ST, QL</i>	<i>T5, ST, QL</i>				
	<i>Hyrnuo 10 mg tablet</i>	<i>T5, PA, QL</i>	<i>T5, PA, QL</i>	<i>T5, PA, QL</i>				
	<i>Loteprednol-tobramycin 0.5-0.3% suspension</i>	<i>T3</i>	<i>T3</i>	<i>T3</i>				
	<i>Shingrix 50 mcg/0.5mL suspension PFS</i>	<i>T1</i>	<i>T1</i>	<i>T1</i>				
	<i>Doptelet 10 mg sprinkle capsule</i>	<i>T5, PA</i>	<i>T5, PA</i>	<i>T5, PA</i>				
	<i>Gammagard ERC 5 gm/50mL solution</i>	<i>T5, PA</i>	<i>T5, PA</i>	<i>T5, PA</i>				
	<i>Gammagard ERC 10 gm/100mL solution</i>	<i>T5, PA</i>	<i>T5, PA</i>	<i>T5, PA</i>				
2026 Formulary Additions – December & January FRF	<i>The Committee reviewed the 2026 Formulary Additions - December & January FRF. The Committee approved as presented:</i>				<i>The Committee reviewed the 2026 Formulary Additions - December & January FRF. It will be sent to CMS for approval. (See attached for voting detail)</i>	<i>S. Jackson</i>	<i>Resolved</i>	
	Drug Name	6T Premium (HMO-SNP)	5T Core (PPO, HMO)	5T Value (PPO, HMO)				
	Protected Classes							
	<i>Brukina 160 mg tablet</i>	<i>T5, PA, QL</i>	<i>T5, PA, QL</i>	<i>T5, PA, QL</i>				
	<i>Ensacove 25, 100 mg capsule</i>	<i>T5, PA, QL</i>	<i>T5, PA, QL</i>	<i>T5, PA, QL</i>				
	<i>Exxua 18.2, 36.3, 54.5, 72.6 mg ER tablet</i>	<i>T5, PA, QL</i>	<i>T5, PA, QL</i>	<i>T5, PA, QL</i>				
	<i>Inhuriyo 200 mg tablet</i>	<i>T5, PA, QL</i>	<i>T5, PA, QL</i>	<i>T5, PA, QL</i>				

TOPIC	DISCUSSION				ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING	DUE DATE
	<i>Koselugo 5, 7.5 mg sprinkle capsule</i>	<i>T5, PA, QL</i>	<i>T5, PA, QL</i>	<i>T5, PA, QL</i>				
	<i>Lomustine 10, 40, 100 mg capsule</i>	<i>T4, PA</i>	<i>T4, PA</i>	<i>T4, PA</i>				
	<i>Pazopanib HCl 400 mg tablet</i>	<i>T5, PA, QL</i>	<i>T5, PA, QL</i>	<i>T5, PA, QL</i>				
	<i>Prezcobix 150-650 mg tablet</i>	<i>T5, QL</i>	<i>T5, QL</i>	<i>T5, QL</i>				
	<i>Subvenite 10 mg/mL suspension</i>	<i>T4</i>	<i>T4</i>	<i>T4</i>				
	<i>Xpovio (80 mg once weekly) 80 mg therapy pack</i>	<i>T5, PA, QL</i>	<i>T5, PA, QL</i>	<i>T5, PA, QL</i>				
	<i>Non-Protected Classes</i>							
	<i>Ampicillin 2000 mg injection</i>	<i>T4</i>	<i>T4</i>	<i>T4</i>				
	<i>Estrogens, conjug 0.3, 0.45, 0.625, 0.9, 1.25 mg tablet</i>	<i>T4</i>	<i>T3</i>	<i>T4</i>				
	<i>Fidaxomicin 200 mg tablet</i>	<i>T5, QL</i>	<i>T5, QL</i>	<i>T5, QL</i>				
	<i>Liomny 0.005, 0.025, 0.05 mcg tablet</i>	<i>T3</i>	<i>T2</i>	<i>T3</i>				
	<i>Luizza 1.5/30 21-day tablet</i>	<i>T3</i>	<i>T2</i>	<i>T3</i>				
	<i>Luizza 1/20 21-day tablet</i>	<i>T3</i>	<i>T2</i>	<i>T3</i>				
	<i>Valtya 1/35 28-day tablet</i>	<i>T2</i>	<i>T2</i>	<i>T2</i>				
2026 December and January FRF Formulary Removals*	<p>The Committee reviewed the 2026 December and January FRF Formulary Removals*. The Committee approved as presented:</p> <ul style="list-style-type: none"> • <i>Brukinsa 80 mg capsule</i> • <i>Endocet 2.5/325, 5/325, 7.5/325, 10/325 mg tablet</i> • <i>Haloette vaginal ring</i> • <i>Neo-Polycin 3.5-400-10000 ointment</i> • <i>Neo-Polycin HC 1% ointment</i> • <i>Norditropin FlexPro 30 mg/3mL solution</i> • <i>Ocella 28 day tablet</i> 				<i>The Committee reviewed the 2026 December and January FRF Formulary Removals*. It will be sent to CMS for approval. (See attached for voting detail)</i>	<i>S. Jackson</i>	<i>Resolved</i>	

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING	DUE DATE
	<ul style="list-style-type: none"> • Ogsiveo 50 mg tablet • Polycin 500-10000 unit/gm ointment • Sulfacetamide sodium 10% ointment • Sumatriptan 8 mg/mL, 12 mg/mL cartridge • Vigpoder 500 mg powder for oral solution <p><i>*These drugs will remain on the formulary until the end of the benefit year</i></p>				
2026 December and January Formulary Removals	<p>The Committee reviewed the 2026 December and January Formulary Removals. The Committee approved as presented.</p> <ul style="list-style-type: none"> • Difucid 200 mg tablet* • Premarin 0.3, 0.45, 0.625, 0.9, 1.25 mg tablet* <p><i>*Brand to be removed, add generic/biosimilar</i></p>	<p>The Committee reviewed the 2026 December and January Formulary Removals. It will be sent to CMS for approval. (See attached for voting detail)</p>	S. Jackson	Resolved	
2026 Quantity Limit Additions	<p>The Committee reviewed the 2026 Quantity Limit Additions. The Committee approved as presented.</p> <ul style="list-style-type: none"> • Brukinsa 160 mg tablet - 60/30 days • Ensacove 25, 100 mg capsule - 60/30 days • Exxua 18.2, 36.3, 54.5, 72.6 mg ER tablet - 30/30 days • Exxua Titration Pack - 32/30 days • Fanapt Titration Pack B tablet - 24/365 days • Fidaxomicin 200 mg tablet - 60/30 days • Hyrnuo 10 mg tablet - 120/30 days • Inluriyo 200 mg tablet - 56/28 days • Koselugo 5 mg sprinkle capsule - 600/30 days • Koselugo 7.5 mg sprinkle capsule - 360/30 days • Pazopanib HCl 400 mg tablet - 60/30 days • Prezcobix 150-650 mg tablet - 30/30 days • Xpovio (80 mg once weekly) 80 mg therapy pack - 4/28 days 	<p>The Committee reviewed the 2026 Quantity Limit Additions. It will be sent to CMS for approval. (See attached for voting detail)</p>	S. Jackson	Resolved	
III. New Drug Review	<p>The following new Protected Class Drugs were reviewed and will be added to the formulary per CMS regulations:</p> <ul style="list-style-type: none"> • Keytruda (pembrolizumab) for Injection • Yescarta (axicabtagene ciloleucel) Suspension for Intravenous Infusion • Darzalex Faspro (daratumumab and hyaluronidase-fihj) Injection • Lunsumio (mosunetuzumab-axgb) Injection • Rubraca (rucaparib) Tablets • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) Injection* • Enhertu (fam-trastuzumab deruxtecan-nxki) Injection • Akeega (abiraterone acetate and niraparib) Tablets 	<p>Per CMS regulations, "The P&T committee will make a reasonable effort to review a new FDA approved drug product (or new FDA approved indication) within 90 days of its release onto the market and</p>	G. Ho	Resolved	

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING	DUE DATE
	<ul style="list-style-type: none"> • <i>Breyanzi (lisocabtagene maraleucel) Suspension for Intravenous Infusion</i> • <i>Jaypirca (pirtobrutinib) Tablets</i> • <i>Imfinzi (durvalumab) Injection</i> • <i>Hyrnuo (sevabertinib) Tablets*</i> • <i>Imdelltra (tarlatamab-dlle) for Injection</i> • <i>Epkinly (epcoritamab-bysp) Injection</i> • <i>Komzifti (ziftomenib) Capsules*</i> • <i>Poherdy (pertuzumab-dpzb) Injection*</i> • <i>Caplyta (lumateperone) Capsules</i> • <i>Revuforj (revumenib) Tablets</i> • <i>Blenrep (belantamab mafodotin-blmf) Injection</i> • <i>Gazyva (obinutuzumab) Injection</i> • <i>Uzedy (risperidone) Extended-Release Injectable Suspension</i> • <i>Subvenite (lamotrigine) Oral Suspension*</i> • <i>Camcevi (leuprolide mesylate) Injection</i> <p><i>The following medications are Formulary with new FDA-approved indications:</i></p> <ul style="list-style-type: none"> • <i>Nexplanon (etonogestrel) Implant</i> • <i>Koselugo (selumetinib) Capsules and Oral Granules</i> • <i>Linzess (linaclotide) Capsules</i> • <i>Winrevair (sotatercept) for Injection</i> • <i>Rybelsus (semaglutide) Tablets</i> • <i>Rinvoq (upadacitinib) Extended-Release Tablets</i> <p><i>The following medications were reviewed and will be kept as Non-formulary. Prior Authorization criteria will be developed as needed:</i></p> <ul style="list-style-type: none"> • <i>Ozempic (semaglutide) Tablets</i> • <i>Yuvezzi (brimonidine tartrate and carbachol) Ophthalmic Solution - formerly Brimochol PF*</i> • <i>Afrezza (insulin human [rDNA origin]) Inhalation Powder</i> • <i>Filkri (filgrastim-laha) Injection*</i> • <i>Zycubo (copper histidinate) Injection - formerly CUTX-101*</i> • <i>Nereus (tradipitant) Capsules*</i> • <i>Yartemlea (narsoplimab-wuug) Injection*</i> • <i>Aqvesme (mitapivat) Tablets*</i> • <i>Cablivi (caplacizumab-yhdp) Injection</i> • <i>Furoscix (furosemide) Injection</i> • <i>Wegovy (semaglutide) Tablets</i> • <i>Accrufer (ferric maltol) Capsules</i> 	<p><i>will make a decision on each new FDA approved drug product (or new FDA approved indication) within 180 days of its release onto the market, or a clinical justification will be provided if this timeframe is not met. Formularies must include substantially all drugs in the six protected categories that are FDA approved by the last CMS specified HPMS formulary upload date for the upcoming contract year. New drugs or newly approved uses for drugs within the six classes that come onto the market after the CMS specified formulary upload date will be subject to an expedited P&T committee review. The expedited review process requires P&T committees to make a decision within 90 days, rather than the normal 180-day requirement. At the end of the 90 day period, these drugs must be added to Part D plan</i></p>			

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING	DUE DATE
	<ul style="list-style-type: none"> • <i>Jascayd (nerandomilast) Tablets</i> • <i>Myqorzo (aficamten) Tablets*</i> • <i>Boncreza (denosumab-mobz) Injection*</i> • <i>Oziltus (denosumab-mobz) Injection*</i> • <i>Nufymco (ranibizumab-leyk) Injection*</i> • <i>Exdensur (depemokimab-ulaa) Injection*</i> • <i>Fesilty (fibrinogen, human-chmt) Lyophilized Powder for Injection*</i> • <i>Addyi (flibanserin) Tablets</i> • <i>Cardamyst (etripamil) Nasal Spray*</i> • <i>Lerochol (lerodalcibep-liga) Injection*</i> • <i>Nuzolvence (zoliflodacin) Granules for Oral Suspension*</i> • <i>Orladeyo (berotralstat) Capsules and Oral Pellets</i> • <i>Daybue (trofinetide) Oral Solution and Powder for Oral Solution</i> • <i>Blujepa (gepotidacin) Tablets</i> • <i>Uplizna (inebilizumab-cdon) Injection</i> • <i>Waskyra (etuvetidigene autotemcel) Suspension for Intravenous Infusion*</i> • <i>Omisirge (omidubicel-olnv) Suspension for Infusion</i> • <i>Avance (acellular nerve allograft-arwx) for Surgical Implantation*</i> • <i>Omlyclo (omalizumab-igec) Injection</i> • <i>Armluppeg (pegfilgrastim-unne) Injection*</i> • <i>Voyxact (sibeprenlimab-szsi) Injection*</i> • <i>Itvisma (onasemnogene abeparvovec-brve) Suspension for Intrathecal Injection*</i> • <i>Eylea HD (aflibercept) Injection</i> • <i>Redemplo (plozasiran) Injection*</i> • <i>Elevidys (delandistrogene moxeparvovec-rokl) Suspension for Intravenous Infusion</i> • <i>Kygevvi (doxycitine and doxribtimine) Powder for Oral Solution*</i> • <i>Osvyrti (denosumab-desu) Injection*</i> • <i>Jubereq (denosumab-desu) Injection*</i> • <i>Conexence (denosumab-bnht) Injection</i> • <i>Stoboclo (denosumab-bmwo) Injection</i> • <i>Lynkuet (elinzanetant) Capsules*</i> • <i>Javadin (clonidine hydrochloride) Oral Solution*</i> • <i>Omvoh (mirikizumab-mrkz) Injection</i> • <i>Contepo (fosfomycin) for Injection*</i> • <i>Tezspire (tezepelumab-ekko) Injection</i> • <i>Epioxa (riboflavin 5'-phosphate) Ophthalmic Solution*</i> • <i>Ferabright (ferumoxytol) Injection*</i> 	<p><i>formularies.” (See attached for voting detail.)</i></p>			

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING	DUE DATE
	<ul style="list-style-type: none"> • <i>Yuflyma (adalimumab-aaty) Injection</i> • <i>Eydenzelt (afibercept-boav) Injection*</i> • <i>Aukelso (denosumab-kyqq) Injection*</i> • <i>Bosaya (denosumab-kyqq) Injection*</i> • <i>Vyjuvek (beremagene geperpavec-svdt) Topical Gel</i> • <i>Bilprevda (denosumab-nxxp) Injection*</i> • <i>Bildyos (denosumab-nxxp) Injection*</i> <p>(* Previously discussed in New Drug Review for Medicaid)</p>				

IV. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held May 2026.



3/17/2026

Danielle Dolores, Director of Pharmacy Services

Date: _____

APPENDIX I: VOTING GRID

	Danielle Dolores, PharmD	George Downs, PharmD	Lawrence Jones, RPh	Tania Kolev, MD	Hannah McCaffrey	Sanjiv Raj	Brian Swift	Kaylei Koerwitz	Heather Scheckner	Merleen Harris-Williams, MD	Demian Elder, MD	Edgar Chou, MD	Comments
<i>Minutes Review/Approval</i>	A	A	A	A	A	E	A	A	A	A	E	A	October 2025
<i>2026 Prior Authorization Criteria Updates – Outlier Review</i>	A	A	A	A	A	E	A	A	A	A	E	A	
<i>2026 Prior Authorization Criteria Updates</i>	A	A	A	A	A	E	A	A	A	A	E	A	
<i>2026 Step Therapy Removals</i>	A	A	A	A	A	E	A	A	A	A	E	A	
<i>2026 Formulary Additions</i>	A	A	A	A	A	E	A	A	A	A	E	A	
<i>2026 Formulary Additions – December & January FRF</i>	A	A	A	A	A	E	A	A	A	A	E	A	
<i>2026 December and January FRF Formulary Removals</i>	A	A	A	A	A	E	A	A	A	A	E	A	
<i>2026 December and January Formulary Removals</i>	A	A	A	A	A	E	A	A	A	A	E	A	
<i>2026 Quantity Limit Additions</i>	A	A	A	A	A	E	A	A	A	A	E	A	
<i>New Drug Review</i>	A	A	A	A	A	E	A	A	A	A	E	A	

*A = Approved as presented * R = Rejected * E = Excused from meeting * P = Precluded from vote due to conflict of interest